Endovascular Engineering, Inc., a Menlo Park, CA-based medical technology company for Pulmonary Embolism, raised $42M in Series B financing.
The round was co-led by 415 Capital and S3 Ventures, with participation of Panakès Partners, M&L Healthcare, and Santé Ventures. Two global strategic investors made substantial commitments alongside Cordis, which continues its strategic partnership with the company.
The company intends to use the funds to advance its new clot removal technology platform for venous thromboembolism (VTE).
Led by CEO Dan Rose, Endovascular Engineering is developing and deploying solutions that advance the standard of care in clot removal. The Hēlo Thrombectomy System is clot removal technology featuring a patented dual-action mechanism that integrates powerful aspiration with advanced mechanical clot disruption. The system delivers large-bore performance through a small-profile catheter, enabling efficient single-pass procedures. The Hēlo catheter is part of a comprehensive system that incorporates additional innovations to enhance patient care, physician experience, and procedural efficiency.
FinSMEs
18/02/2025